Inhibition of severe acute respiratory syndrome-associated coronavirus (SARS-CoV) infectivity by peptides analogous to the viral spike protein
- 17 April 2006
- journal article
- Published by Elsevier in Virus Research
- Vol. 120 (1-2) , 146-155
- https://doi.org/10.1016/j.virusres.2006.03.001
Abstract
No abstract availableKeywords
This publication has 61 references indexed in Scilit:
- Implication of proprotein convertases in the processing and spread of severe acute respiratory syndrome coronavirusBiochemical and Biophysical Research Communications, 2004
- Following the rule: formation of the 6-helix bundle of the fusion core from severe acute respiratory syndrome coronavirus spike protein and identification of potent peptide inhibitorsBiochemical and Biophysical Research Communications, 2004
- The Coronavirus Spike Protein Is a Class I Virus Fusion Protein: Structural and Functional Characterization of the Fusion Core ComplexJournal of Virology, 2003
- A phase II clinical study of the long-term safety and antiviral activity of enfuvirtide-based antiretroviral therapyAIDS, 2003
- Energetics, stability, and prediction of transmembrane helices11Edited by G. von HeijneJournal of Molecular Biology, 2001
- Similar Structural Models of the Transmembrane Proteins of Ebola and Avian Sarcoma VirusesCell, 1996
- Peptides from conserved regions of paramyxovirus fusion (F) proteins are potent inhibitors of viral fusion.Proceedings of the National Academy of Sciences, 1996
- A Synthetic Peptide from HIV-1 gp41 Is a Potent Inhibitor of Virus-Mediated Cell—Cell FusionAIDS Research and Human Retroviruses, 1993
- A General Model for the Transmembrane Proteins of HIV and Other RetrovirusesAIDS Research and Human Retroviruses, 1989
- Specific inhibition of paramyxovirus and myxovirus replication by oligopeptides with amino acid sequences similar to those at the N-termini of the Fl or HA2 viral polypeptidesVirology, 1980